3rd University Department of Internal Medicine, SOTIRIA Athens General Hospital of Chest Diseases
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Poulakou, Garyfallia
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
REACT, NCT06294600: Clarithromycin Treatment to Prevent Sepsis Progression in CAP

Recruiting
3
330
Europe
Clarithromycin 500mg, A β-lactam/β-lactamase inhibitor or a 3rd generation cephalosporin or a fluoroquinolone, Tablets
Hellenic Institute for the Study of Sepsis
Community-acquired Pneumonia
11/25
01/26
INSIGHT12, NCT04910269 / 2021-001663-24: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
NCT05279352 / 2021-002390-25: Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

Recruiting
2a
30
Europe
FBR-002, Placebo
Fab'entech, European Commission (Hera incubator - EPIC Crown-2 project)
COVID-19
06/22
07/22
NCT04902183 / 2021-002184-22: Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

Recruiting
2
90
Europe
CovenD24, Exo-CD24
Athens Medical Society, OBCTCD24 Ltd, Elpen Pharmaceutical Co. Inc.
Covid19
09/21
09/21
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT06694701: Emapalumab Treatment for Anticipated Clinical Benefit in Sepsis Driven by the Interferon-Gamma Endotype (The EMBRACE Trial)

Recruiting
2
75
Europe
Emapalumab-Izsg, Emapalumab Group 1, Emapalumab Group 2, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
11/26
11/26
BIOARTE, NCT06141395: NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

Completed
N/A
100
Europe
NGS-based assay for bacterial identification
Hellenic Institute for the Study of Sepsis, The BioArte
Pneumonia, Acute Pyelonephritis, Bacteremia, Biliary Tract Infection
03/24
03/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Poulakou, Garyfallia
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
REACT, NCT06294600: Clarithromycin Treatment to Prevent Sepsis Progression in CAP

Recruiting
3
330
Europe
Clarithromycin 500mg, A β-lactam/β-lactamase inhibitor or a 3rd generation cephalosporin or a fluoroquinolone, Tablets
Hellenic Institute for the Study of Sepsis
Community-acquired Pneumonia
11/25
01/26
INSIGHT12, NCT04910269 / 2021-001663-24: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
NCT05279352 / 2021-002390-25: Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

Recruiting
2a
30
Europe
FBR-002, Placebo
Fab'entech, European Commission (Hera incubator - EPIC Crown-2 project)
COVID-19
06/22
07/22
NCT04902183 / 2021-002184-22: Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

Recruiting
2
90
Europe
CovenD24, Exo-CD24
Athens Medical Society, OBCTCD24 Ltd, Elpen Pharmaceutical Co. Inc.
Covid19
09/21
09/21
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT06694701: Emapalumab Treatment for Anticipated Clinical Benefit in Sepsis Driven by the Interferon-Gamma Endotype (The EMBRACE Trial)

Recruiting
2
75
Europe
Emapalumab-Izsg, Emapalumab Group 1, Emapalumab Group 2, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
11/26
11/26
BIOARTE, NCT06141395: NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

Completed
N/A
100
Europe
NGS-based assay for bacterial identification
Hellenic Institute for the Study of Sepsis, The BioArte
Pneumonia, Acute Pyelonephritis, Bacteremia, Biliary Tract Infection
03/24
03/24

Download Options